You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology I1 Apr 2017MP44-17 PATIENT DERIVED XENOGRAFTS AS PRECLINICAL MODELS OF UROLOGICAL MALIGNANCIES Sofia Karkampouna, Eugenio Zoni, Federico la Manna, Letizia Astrologo, Lijkele Beimers, Peter Kloen, Joel Grosjean, Irena Klima, Martin Spahn, Marianna Kruithof-de Julio, and George N. Thalmann Sofia KarkampounaSofia Karkampouna More articles by this author , Eugenio ZoniEugenio Zoni More articles by this author , Federico la MannaFederico la Manna More articles by this author , Letizia AstrologoLetizia Astrologo More articles by this author , Lijkele BeimersLijkele Beimers More articles by this author , Peter KloenPeter Kloen More articles by this author , Joel GrosjeanJoel Grosjean More articles by this author , Irena KlimaIrena Klima More articles by this author , Martin SpahnMartin Spahn More articles by this author , Marianna Kruithof-de JulioMarianna Kruithof-de Julio More articles by this author , and George N. ThalmannGeorge N. Thalmann More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1348AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Prostate and bladder cancer (PCa, BLCa) are highly frequent and metastatic urological malignancies. Relevant models for the study of tumor heterogeneity and drug resistance mechanisms are required. Patient-derived xenografts (PDX) comprise excellent tools for the maintenance of the molecular and functional properties of the original tumor and allow the long-term study and in vivo drug response assays. The objective is to establish PDX models from primary and metastatic PCa and BLCa, which are currently of limited availability, and to develop a platform for standardized characterization and drug response tests of the PDX tumors in vivo and in ex vivo tissue slices system. METHODS PDX are generated by needle biopsy implantation (PCa, BLCa) subcutaneously in immunocompromised NOD SCID gamma mice. Tumors are serially transplanted in vivo. Histopathological and RNA analysis of the different passages of PDX tumors is performed to identify morphological and molecular similarities with the original tumor. As preclinical model, PDX tumors are maintained ex vivo (ten days) and used for drug testing assays based on the standard treatment used for primary types of PCa and BLCa. RESULTS PDX models from primary and metastatic PCa and BLCa (BMURO) maintain morphology similar to the original tumor. Tumors (clinical specimens, PDXs) are tested in ex vivo drug response assays using our developed methodology on whole tissue slice culture system. Histological morphology of Lymph node-PCa tumor slices is affected by exposure to cytostatic agents (cabazitaxel, docetaxel). Bone metastasis BLCa (BMURO) tumor slices treated ex vivo with drug compounds exhibit morphological changes at the lowest concentrations of cisplatin and gemcitabine. Ongoing studies aim to address whether the ex vivo and in vivo PDX drug response recapitulates the individual drug response observed during clinical treatment prior to surgery. CONCLUSIONS Xenograft models are promising tools for the study of personalized treatment and drug resistance mechanisms in PCa and BLCa. The ex vivo drug response assays on PDX tumor slices represent an experimental screening platform of patient-specific drug responses. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e570 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Sofia Karkampouna More articles by this author Eugenio Zoni More articles by this author Federico la Manna More articles by this author Letizia Astrologo More articles by this author Lijkele Beimers More articles by this author Peter Kloen More articles by this author Joel Grosjean More articles by this author Irena Klima More articles by this author Martin Spahn More articles by this author Marianna Kruithof-de Julio More articles by this author George N. Thalmann More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...